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Abstract
BACKGROUND—Chronic hepatitis C virus (HCV) infection is a cause of major complications
in persons who are also infected with the human immunodeficiency virus (HIV). However, the
treatment of HCV infection in such persons has been associated with a high rate of intolerance and
a low rate of response. We conducted a multicenter, randomized trial comparing peginterferon
plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons
coinfected with HIV.
METHODS—A total of 66 subjects were randomly assigned to receive 180 μg of peginterferon
alfa-2a weekly for 48 weeks, and 67 subjects were assigned to receive 6 million IU of interferon
alfa-2a three times weekly for 12 weeks followed by 3 million IU three times weekly for 36
weeks. Both groups received ribavirin according to a dose-escalation schedule. At week 24,
subjects who did not have a virologic response (those who had an HCV RNA level greater than or
equal to 60 IU per milliliter) underwent liver biopsy, and medications were continued in subjects
with either a virologic response or histologic improvement.
RESULTS—Treatment with peginterferon and ribavirin was associated with a significantly
higher rate of sustained virologic response (an HCV RNA level of less than 60 IU per milliliter 24
weeks after completion of therapy) than was treatment with interferon and ribavirin (27 percent vs.
12 percent, P=0.03). In the group given peginterferon and ribavirin, only 14 percent of subjects
with HCV genotype 1 infection had a sustained virologic response (7 of 51), as compared with 73
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percent of subjects with an HCV genotype other than 1 (11 of 15, P<0.001). Histologic responses
were observed in 35 percent of subjects with no virologic response who underwent liver biopsy.
CONCLUSIONS—In persons infected with HIV, the combination of peginterferon and ribavirin
is superior to the combination of interferon and ribavirin in the treatment of chronic hepatitis C.
These regimens may provide clinical benefit even in the absence of virologic clearance. The
marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates
that strategies are needed to improve the outcome in persons infected with HCV genotype 1.
Coinfection with hepatitis c virus (HCV) is common among persons infected with the
human immunodeficiency virus (HIV), with a prevalence ranging from 4 to 92 percent
depending on the underlying risk factors. Since the introduction of potent antiretroviral
therapy, liver disease due to HCV coinfection has become a major source of mortality
among HIV-infected persons.1-3 The progression of liver disease appears to be accelerated
in such persons.4
Treatment regimens based on interferon and ribavirin are recommended for chronic hepatitis
C but pose special concerns in persons coinfected with HIV, particularly those who are
receiving antiretroviral therapy. Common side effects of treatment, such as depression,
anemia, and lymphopenia, may be exacerbated. Ribavirin may interfere with thymidine
analogues such as zidovudine and stavudine5,6 and may potentiate the toxic effects of
didanosine.7 To date, the few studies examining the effect of interferon and ribavirin in
patients coinfected with HCV and HIV have had disappointing rates of sustained virologic
response and high rates of intolerable side effects.8,9 More recently, the use of peginterferon
with ribavirin has significantly improved the rates of virologic response in patients with
HCV infection alone.10,11 We therefore conducted a multicenter, randomized, controlled
trial comparing peginterferon plus ribavirin with interferon plus ribavirin in the treatment of
HCV infection in subjects coinfected with HIV.
METHODS
SELECTION OF SUBJECTS
The Adult AIDS Clinical Trials Group (ACTG) A5071 was a prospective study conducted at
21 ACTG sites in the United States. HIV-infected subjects 18 years of age or older were
eligible to participate if they had a confirmed diagnosis of chronic hepatitis C, as defined by
an HCV RNA level of more than 600 IU per milliliter, and had not previously been treated
with interferon alfa. A liver biopsy demonstrating abnormal histologic findings consistent
with the presence of chronic hepatitis C was required within 48 weeks before study entry.
Subjects with cirrhosis were eligible provided they had no evidence of hepatic
decompensation (i.e., as-cites, encephalopathy, jaundice, hypoalbuminemia, or
coagulopathy). Subjects who had normal or elevated serum alanine aminotransferase levels
were eligible.
Subjects were stratified into two groups according to their history of HIV therapy: subjects
whose antiretroviral-therapy regimen had been stable for at least 12 weeks with CD4 cell
counts of more than 100 per cubic millimeter and less than 10,000 copies of HIV type 1
(HIV-1) RNA per milliliter, and subjects with CD4 cell counts of more than 300 per cubic
Chung et al. Page 2






















millimeter who had never received antiretroviral agents and who were not planning to begin
HIV therapy during the trial. Subjects were excluded if they had clinically significant
anemia, neutropenia, or thrombocytopenia; renal disease; positive tests for hepatitis B
surface antigen; uncontrolled cardiopulmonary disease; poorly controlled psychiatric
disease; or an active HIV-related opportunistic infection.
STUDY DESIGN
Figure 1 shows the design of the study. Subjects were randomly assigned to receive either
180 μg of peginterferon alfa-2a subcutaneously weekly plus ribavirin (600 mg per day for 4
weeks, 800 mg per day for 4 weeks, and then 1000 mg per day for the remainder of the
study) or 6 million IU of interferon alfa-2a subcutaneously three times weekly for 12 weeks
followed by 3 million IU subcutaneously three times weekly for the remainder of the study
plus the same regimen of ribavirin used in the first group. The dose of ribavirin was
increased in a stepped fashion to reduce the treatment-limiting anemia previously observed
in persons coinfected with HCV and HIV.8 At randomization, stratification variables
included the HCV genotype (genotype 1 vs. other genotypes) and antiretroviral-therapy
status (current antiretroviral therapy vs. no antiretroviral therapy). The study was designed
to have a statistical power of 80 percent (with a two-sided alpha value of 0.05) to detect an
absolute difference in the rate of virologic response between groups of 30 percent. The
target sample size of 132 was adjusted for a group-sequential design.
An efficacy and safety assessment was performed in all subjects at week 24 to determine
whether they could continue to participate. Subjects who had a virologic response (defined
as an HCV RNA level of less than 60 IU per milliliter) continued treatment until week 48, at
which time a liver biopsy was performed. Subjects who had no virologic response at week
24 were required to undergo liver biopsy at that time. Subjects who had a histologic
response, as defined by an improvement in the total hepatic activity index12 of at least two
points, as judged by a central pathologist, were also permitted to continue treatment until
week 48. Subjects who did not have a virologic response at week 24 and subjects who either
had no histologic response or did not undergo liver biopsy stopped taking the study drug.
Subjects were followed for an additional 24 weeks after the completion of therapy. HCV
RNA levels were assessed at entry and at weeks 4, 8, 12, 36, and 60 with the use of a
quantitative RNA assay (lower limit of detection, 600 IU per milliliter, Roche Cobas
Amplicor 2.0) and at weeks 24, 48, and 72 with the use of a qualitative RNA assay (lower
limit of detection, 60 IU per milliliter, Roche Cobas Amplicor 2.0).
HCV genotyping was performed on all subjects at entry with the use of a line-probe assay
(LiPA, Innogenetics). Results were reported as genotype 1 or a genotype other than 1.
The institutional review boards of the participating sites approved the protocol, and all
subjects provided written informed consent. An external data and safety monitoring board
reviewed the study design and the results of one interim analysis.
The study was funded by the National Institutes of Health. The drugs and diagnostic kits for
the detection of HCV RNA were provided by Roche Laboratories. The study investigators
had access to all of the study data, took responsibility for the accuracy of the analysis, and
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had full and independent authority over the preparation of the manuscript and decisions
concerning publication.
ASSESSMENT OF EFFICACY AND SAFETY
Because of concern about the safety of administering these drugs to subjects who were
coinfected with HIV, we used the primary end points of viro-logic response and safety at
week 24. Secondary end points included a sustained virologic response, defined by an HCV
RNA level of less than 60 IU per milliliter 24 weeks after the completion of therapy,
allowing a 6-week window for the sample; a viro-logic response at the end of treatment, as
defined by an HCV RNA level of less than 60 IU per milliliter at the completion of therapy;
an early virologic response, as defined by the clearance of HCV RNA or a reduction in HCV
RNA levels by more than 2 log (on a base-10 scale) IU per milliliter at 12 weeks of
treatment; a histologic response; changes in the control of HIV disease, as defined by
changes in the CD4 cell count, percentage of CD4 cells, and HIV-1 RNA levels; or
development of an AIDS-defining illness. HIV-1 RNA was assessed with the use of an assay
(Roche Cobas Amplicor 2.0) with a lower limit of detection of 50 copies per milliliter. All
data were analyzed according to the intention to treat.
Safety was assessed at weeks 1, 2, and 4 and every 4 weeks thereafter and 12 and 24 weeks
after the discontinuation of the study drug. Specific end points were the incidence of grade 3
(severe) or 4 (life-threatening) adverse events13 and the premature discontinuation of
treatment.
Subjects who discontinued treatment prematurely because of intolerance to the study drug
were encouraged to remain in the study. Stepwise reductions in the doses of peginterferon to
135, 90, or 45 μg weekly and reductions in ribavirin doses to 600 mg per day were permitted
to manage adverse events or abnormalities in laboratory values that reached predetermined
thresholds of severity. If the adverse event resolved or improved, a return to the initial
dosing level was permitted unless the subject had received the reduced dose for more than
four weeks. Subjects were withdrawn from treatment if they missed three or more
consecutive doses or at the discretion of the investigator. The use of supplemental
hematopoietic growth factors (epoietin alfa and filgrastim) was permitted.
STATISTICAL ANALYSIS
Associations between dichotomous variables were evaluated with Fisher's exact test.
Associations involving ordered categorical data or continuous data were evaluated with a
Wilcoxon test adjusted for ties. Univariate- and multicovariate-adjusted P values for the
association of the virologic response at week 24 with covariates were evaluated with logistic
regression stratified according to the HCV genotype and HIV treatment history. All P values
are two-sided. Univariate analyses of sustained virologic response were performed with log-
rank tests, and multicovariate analyses with proportional-hazards regression. Because of the
limited sample size and because sustained virologic response was not a primary objective,
these tests were not stratified according to the group or the HCV genotype. The proportion
of subjects who continued to have sustained virologic response was estimated with the use
of the life-table method.
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A total of 134 subjects were enrolled between December 2000 and June 2001. One subject
was excluded from analyses because he did not meet the entry criteria; he did not receive
treatment. Table 1 depicts the baseline characteristics of the 133 eligible subjects. All
received at least one dose of study medication. The pretreatment characteristics of the
subjects in the two groups were similar, including age, sex, race or ethnic group, and
performance status. Eighty-six percent of subjects were receiving stable antiretroviral
therapy; 60 percent of subjects had fewer than 50 copies of HIV-1 RNA per milliliter. The
median CD4 cell counts were nearly 500 per cubic millimeter. The median HCV RNA
levels were high, with levels exceeding 106 IU per milliliter in 82 percent of subjects.
Seventy-eight percent had HCV genotype 1 infection, and 67 percent had abnormal alanine
aminotransferase levels. Baseline histologic findings were similar in the two groups. Ten
percent of subjects had evidence of cirrhosis (as defined by a fibrosis stage of 5 or 6).
VIROLOGIC RESPONSE
The rates of virologic response at week 24 and at the end of treatment were higher in the
group given peginterferon and ribavirin than in the group given interferon and ribavirin
(Table 2). At week 24, 44 percent of subjects in the group given peginterferon and ribavirin
had a virologic response, as compared with 15 percent of those in the group given interferon
and ribavirin (P<0.001), and the rates of virologic response at the end of treatment were 41
percent and 12 percent, respectively (P<0.001) (Table 2).
Receipt of peginterferon and ribavirin was associated with a significantly higher rate of
sustained virologic response (27 percent, vs. 12 percent in the group given interferon and
ribavirin; P=0.03). As with HCV monoinfection, there was a significant disparity in
response rates in both groups between subjects infected with HCV genotype 1 and those
infected with other HCV genotypes. For those with genotype 1 infections, the rate of
sustained virologic response was only 14 percent in the group given peginterferon and
ribavirin and 6 percent in the group given interferon and ribavirin, whereas for those
infected with other HCV genotypes (predominantly genotypes 2 and 3), the respective rates
of sustained virologic response were 73 percent and 33 percent (P<0.001 for the comparison
with genotype 1 infections). The observed decrement in the rate of sustained virologic
response from the end-of-treatment virologic response in the group given peginterferon and
ribavirin was attributable to a high relapse rate among those with HCV genotype 1 infection.
PREDICTORS OF A SUSTAINED VIROLOGIC RESPONSE
Receipt of peginterferon and ribavirin, an HCV genotype other than 1, the absence of prior
injection-drug use, a detectable level of HIV-1 RNA at entry, and a Karnofsky score of 100
were predictive of a sustained virologic response in univariate analysis (Table 3). In
multivariate analysis, all of these variables but the Karnofsky score independently predicted
a sustained virologic response. The baseline CD4 cell count, percentage of CD4 cells, age,
race or ethnic group, body weight, HCV RNA level, use or nonuse of any antiretroviral
therapy, use or nonuse of protease inhibitors, baseline HIV RNA level, use or nonuse of
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supplemental growth factors, and pretreatment histologic findings were not predictive of a
sustained virologic response.
EARLY VIROLOGIC RESPONSE
Of the 106 subjects in whom HCV RNA levels were measured at week 12 (Fig. 2), 43 (41
percent) had an early virologic response. Twenty-two of these 43 subjects (51 percent) had a
sustained virologic response. In contrast, none of the 63 subjects who did not have an early
virologic response had a sustained virologic response (negative predictive value, 100
percent).
HISTOLOGIC RESPONSE
Among the subjects with no virologic response at week 24, 45 of 57 subjects in the group
given interferon and ribavirin (79 percent) underwent liver biopsy, as did 26 of 37 subjects
in the group given peginterferon and ribavirin (70 percent). A histo-logic response was
observed in 25 of these 71 subjects (35 percent), 36 percent of such subjects in the group
given interferon and ribavirin and 35 percent of such subjects in the group given
peginterferon and ribavirin. The magnitude of the reduction in HCV RNA levels among
subjects with a histologic response did not differ from that among those without a histologic
response, indicating that a partial virologic response did not predict histologic improvement.
Among the 39 subjects with a virologic response at week 24, 27 underwent a biopsy at week
48. Fourteen of these 27 subjects (52 percent) had a histo-logic improvement, 11 (41
percent) had no change, and 2 (7 percent) had worsening disease.
SAFETY AND ADVERSE EVENTS
Eight subjects in each group (12 percent) were prematurely withdrawn from treatment
because of abnormalities in laboratory values or other adverse events, and the rates were
similar to the rates of premature withdrawal in studies of subjects with HCV monoinfection
who received similar treatments.12,13 Of the 16 such subjects, 3 declined further
participation and 1 died of causes unrelated to HCV infection or treatment. The remaining
12 were withdrawn from the study because of either neuropsychiatric issues (primarily
depression) or the need to manage multiple signs and symptoms and abnormal laboratory
values. Similar numbers of subjects in each group had grade 2 or 3 influenza-like symptoms
and grade 2 or 3 depression during treatment (Table 4). There were no significant
differences between groups in the frequency of grade 2 or higher decreases in hemoglobin;
such decreases occurred in few subjects. Neutro-phil counts decreased in both groups,
particularly during the first two weeks of treatment. Two subjects in the group given
peginterferon and ribavirin discontinued therapy because of grade 4 neutropenia (defined as
fewer than 500 neutrophils per cubic millimeter). In six others (three in each group), grade 4
neutropenia was successfully managed with a dose reduction, with or without the addition of
hematopoietic growth factor. Grade 4 thrombocytopenia occurred in only one subject in the
group given peginterferon and ribavirin.
Although grade 2 or 3 elevations in lipase were observed in nine subjects in each group
during the first 24 weeks, there was only one clinically significant episode of pancreatitis
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requiring hospitalization and the discontinuation of treatment at week 16. The subject was
also receiving didanosine. Of the 18 subjects with lipase elevations of grade 2 or higher,
only 4 were taking didanosine. A single grade 3 elevation in lactate was noted in one
subject, but it did not require the discontinuation of treatment. One subject died of
complications related to Hodgkin's disease; this event was thought to be unrelated to the
study medications. There were no AIDS-defining illnesses.
EFFECTS ON THE CONTROL OF HIV DISEASE
The median CD4 cell count fell from entry to week 24 in both groups (by 130 cells per cubic
millimeter in the group given peginterferon and ribavirin and by 103 cells per cubic
millimeter in the group given interferon and ribavirin, P=0.04); however, the percentage of
CD4 cells actually increased in both groups (by 3.5 percent and 3.0 percent, respectively).
For the subjects who continued treatment until week 48, the absolute CD4 cell count did not
decrease further and returned to baseline 24 weeks after treatment was stopped.
A total of 119 subjects had data on HIV-1 RNA levels available at baseline and week 24.
Fifty-four percent of subjects in the group given interferon and ribavirin and 52 percent of
those in the group given peginterferon and ribavirin had undetectable levels of HIV-1 RNA
at both times. Another 29 percent in each group had detectable levels of HIV-1 RNA at both
times. Six percent of subjects in the group given interferon and ribavirin and 5 percent of
those given peginterferon and ribavirin had undetectable levels at baseline and detectable
levels of HIV-1 RNA at 24 weeks. Eleven percent and 14 percent, respectively, had initially
detectable levels that were undetectable at 24 weeks.
DISCUSSION
We conducted a multicenter, randomized, controlled trial of peginterferon and ribavirin and
interferon and ribavirin in subjects who were coinfected with HCV and HIV. The
combination of peginterferon and ribavirin was significantly more effective in achieving a
sustained virologic response than was the combination of interferon and ribavirin. However,
the rate of sustained virologic response with peginterferon and ribavirin therapy was
considerably lower than the rates among patients with HCV monoinfection who received
similar therapy,10,11 despite the relatively high CD4 cell counts in our cohort.
We observed an even more dramatic disparity in the response of different HCV genotypes
than was observed in patients with HCV monoinfection. The rate of sustained virologic
response after peginterferon and ribavirin in HIV-infected subjects with HCV genotype 2 or
3 infection approached historical rates in subjects with HCV monoinfection (which are 75 to
82 percent), but the rate of response to interferon and ribavirin was lower.10,11 However,
there was a marked dropoff in the rate of sustained response among subjects with HCV
genotype 1 and HIV infection, as compared with historical rates among subjects with HCV
monoinfection (42 to 45 percent).10,11 Among subjects who received peginterferon and
ribavirin, the large decrease in the rate of sustained virologic response was driven primarily
by a high relapse rate in those with HCV genotype 1 infection. The use of peginterferon and
ribavirin in patients coinfected with HCV genotype 1 and HIV should therefore be carefully
weighed against this low projected rate of response.
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There are several potential explanations for the diminished rates of antiviral response: HCV
RNA levels are higher in subjects with HIV coinfection than in those with HCV
monoinfection; the cumulative doses of ribavirin received in this dose-escalation regimen
may have been, either because of the study design or because of dose reductions, insufficient
to prevent relapse; and qualitative rather than quantitative defects in the cellular immune
response may underlie the failure to clear HCV. Investigation of new treatment strategies,
including use of dose-optimized ribavirin, will be required to improve response rates and
decrease relapse rates among patients coinfected with HCV genotype 1 and HIV.
Adherence to treatment has been cited as a potentially important factor in determining the
outcome. We did not specifically examine adherence, since detailed pill or injection counts
were not performed. Although information regarding dose-modification events is available
to us, the complex nature of the study design, in which only subjects with a virologic
response or subjects with a histo-logic response but not a virologic response were permitted
to continue therapy beyond 24 weeks (a total of 64 subjects), limits our ability to perform a
meaningful analysis of the relationship between adherence and a sustained virologic
response.
The rate of premature discontinuation of 12 percent was similar to the rates in studies of
HIV-negative subjects with chronic hepatitis C10,11 and was perhaps lower than those in
prior studies of interferon and ribavirin in subjects coinfected with HCV and HIV, in which
dropout rates approached 30 percent.8,9 This favorable outcome may have been attributable
to the dosing schedule for ribavirin, which was designed to maximize the retention of study
subjects.
Furthermore, antiviral therapy for HCV had no adverse effect on the control of HIV disease.
Interferon has broadly suppressive effects on leukocytes, and the finding of reduced CD4
cell counts was therefore not surprising; however, the percentage of CD4 cells actually
increased, and HIV-1 RNA levels did not change appreciably during the study. Most
important, no clinical progression of HIV to AIDS was observed during the study period.
The surprising finding that the presence of detectable HIV-1 RNA levels at entry was
associated with a sustained virologic response to HCV therapy may reflect several factors:
the enrollment of subjects with relatively preserved CD4 cell counts who had not received
antiretroviral therapy or of subjects who had not been receiving antiretroviral therapy long
enough to have complete virologic suppression and the association of HIV suppression with
increases in HCV RNA.14 Alternatively, given that this finding was the result of an
exploratory analysis of a secondary end point, it may represent a type I error. Confirmation
in other studies will be important.
Because of the importance of the progression of liver disease in subjects who are coinfected
with HCV and HIV, we also assessed histologic responses in both those with a virologic
response and those without a virologic response. It is consistent with the observed effects of
combination antiviral therapy on liver histologic findings that the majority of subjects with a
virologic response had a histologic response. We also found that among subjects without a
virologic response who underwent liver biopsy, over one third had histologic evidence of
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improvement, despite the absence of a significant decrease in HCV viremia. These data
suggest that interferon-based therapy has benefits that are independent of its antiviral effects
and support the need for investigation of maintenance strategies, especially among subjects
coinfected with HCV and HIV who have moderate-to-advanced fibrosis. Maintenance
therapy with interferon could be given for extended periods at doses that do not clear the
virus but may halt or slow the progression of liver fibrosis, as has been done in subjects with
HCV monoinfection.15 These data take on even greater relevance in the light of the low
rates of response to interferon therapy in subjects coinfected with HCV genotype 1 and HIV.
Since the absence of markers of an early viro-logic response uniformly predicted the futility
of treatment, early discontinuation of antiviral therapy at 12 weeks should be considered in
patients with minimal or no fibrosis who do not have a reduction in HCV RNA levels by a
factor of 100 from baseline. However, therapy should be continued in patients with more
advanced disease, since the goal of treatment is slowing the progression of liver disease
rather than eradicating the virus.
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Predictive Value of an Early Virologic Response.
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Table 1
Baseline Characteristics ofthe Subjects.
*
Characteristic Interferon and Ribavirin (N=67) Peginterferon and Ribavirin (N =66)
Male sex (%) 85 79
Race or ethnic group (%)
†
    White 46 50
    Black 34 32
    Hispanic 12 15
    Other 8 3
Age (yr) 44 45
Karnofsky score× 90 90
Median CD4 cell count (no./mm3) 453 495
HIV-1 RNA level <50 copies/ml (%) 60 61
Receiving antiretroviral therapy (%)
‡ 87 85
HCV RNA level (×10-6 IU/ml)
§ 6.2±0.3 6.2±0.4
HCV RNA level >1×106 lU/ml (%) 82 83
HCV genotype 1 (%)
‡ 78 77
Abnormal alanine aminotransferase level (%) 68 66







There were no significant differences between the groups.
†
Race or ethnic group was self-reported by the subjects.
‡
This was a stratification variable.
§
Plus-minus values are means ±SD.
¶
Scores can range from 0 to 18, with higher scores indicating more activity.12
∥
Scores can range from 0 to 6, with higher scores indicating more extensive fi-brosis.12
**
Cirrhosis was defined by fibrosis of stage 5 or 6.















































no. (%) no. (%) no. (%)
At week 24 10 (15) 29 (44) <0.001 4 (8)
17 (33)
* 6 (40) 12 (80)
At end of treatment 8 (12) 27 (41) <0.001 3 (6) 15 (29) 5 (33)
12 (80)
†






P=0.001 for the comparison with the group given interferon and ribavirin.
†
P<0.001 for the comparison with the subjects in the same group with a genotype 1 infection.
‡
P=0.07 for the comparison with the group given interferon and ribavirin with a non-genotype 1 infection.
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Table 3
Predictors of a Sustained Virologic Response.
Factor P Value Odds Ratio (95% CI)
Univariate Analysis Multivariate Analysis
Treatment with peginterferon and ribavirin (vs. interferon and
ribavirin)
0.03 0.008 4.76 (1.49-15.2)
Non-genotype 1 infection (vs. genotype 1 infection) <0.001 <0.001 15.8 (4.94-50.5)
Prior injection-drug use (vs. no prior use) 0.039 0.009 0.48 (0.27-0.83)
HIV-1 RNA detectable at baseline (vs. undetectable) 0.046 0.023 3.55 (1.19-10.6)




This factor did not meet criteria for retention in the multicovariate model.
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